(Reuters)—Pharmaceutical companies have ramped up clinical trials in the past month, rebounding from a steep decline in activity following the start of the COVID-19 outbreak, though activity remains below pre-pandemic levels, according to new research shareS with Reuters. The research, which was prepared by clinical trial consulting firm Medidata, shows that new subjects entered trials…
The ACR/CHEST ILD Guidelines in Practice, a video
In collaboration with the American College of Chest Physicians, the ACR released two new comprehensive guidelines aimed at improving the screening, monitoring, and treatment of patients with interstitial lung disease (ILD) secondary to systemic autoimmune rheumatic diseases (SARDs). Recently, Sindhu R. Johnson, MD, PhD, professor of medicine at the University of Toronto, Canada, director of the Toronto Scleroderma Program and principal investigator for the guideline, and Elana J. Bernstein, MD, MSc, Florence Irving associate professor of medicine in the Division of Rheumatology at Columbia University, New York City, and co-first author, presented a webinar to talk about how the guidelines were developed and present some of the recommendations and their rationale: Watch the recording now!

Bone Density Concerns: Guidance on Tackling Fracture Risk in CKD
Suggestions on how to assess risk and manage bone issues in chronic kidney disease patients are offered…

Biologic Treatment Recommendations for Rheumatic Disease Patients Who Contract COVID-19
COVID-19 Global Alliance registry and other data on rheumatic disease patients with COVID-19 were presented…
Joint Letter to CMS Advocates Against Adding Stelara to Self-Administered Drug List
The ACR, CSRO and Arthritis Foundation asked the Centers for Medicare & Medicaid Services to review the decision to add Stelara to the Self-Administered Drugs list, which would limit access for patients who can’t self-administer.
Biosimilar Prescribing Habits in the VA & Academic Settings
In a new study, Baker et al. examined reference product and biosimilar orders, comparing data from a Veterans Affairs Medical Center (VAMC) to those from an academic medical center…

Research Beyond COVID-19: Collateral Damage
COVID-19 has generated an outpouring of fast-paced, late-breaking new developments. The majority of countries (188) around the world have reported cases of COVID-19.1 As of April 1, 2020, the Centers for Disease Control and Prevention had reported cases in every U.S. jurisdiction (50 states, District of Columbia, Puerto Rico, Guam, the Northern Mariana Islands and…

More Money, More Research: Foundation Report Sheds Light on Funding Gaps
The ACR and Rheumatology Research Foundation hope a new report on rheumatic disease research can leverage more money for ACR members, funding future research…

EULAR & ACR COVID-19 Recommendations: How to Manage Patients During the COVID-19 Pandemic
ACR & EULAR recommendations for the treatment of patients with rheumatic illness during the COVID-19 pandemic are explored…
ACR Releases COVID-19 Clinical Guidance for Pediatric Patients
The ACR has developed two new clinical guidance documents for pediatric patients in the context of the COVID-19 pandemic.

Foundation’s Award Provides Research Opportunity for Community-Based Practitioners
Rheumatologists in community-based practices work closely with patients, which allows them to notice trends and nuances researchers may not. Unfortunately, few opportunities exist for rheumatologists to test their observations through research, in addition to taking care of patients. Limited funding, time constraints and competition from larger academic medical centers are some of the barriers that…
- « Previous Page
- 1
- …
- 81
- 82
- 83
- 84
- 85
- …
- 305
- Next Page »